Virological treatment outcome under HAART: does sex matter? by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Virological treatment outcome under HAART: does sex matter?
AE Haberl*1, S Usadel2, N Hanhoff3 and S Holm4
Address: 1Hospital of the JW Goethe University Frankfurt, Frankfurt, Germany, 2Private Practice in Cooperation with the Department of Infectious 
Diseases of the University Freiburg, Germany, 3DAGNÄ, Aachen, Germany and 4Private Practice, Hannover, Germany
* Corresponding author    
Background
In Germany, 17% of 59,000 persons living with HIV/AIDS
are female. Accordingly, the research focus in clinical stud-
ies as well as in cohort analyses has been almost exclu-
sively on HIV-positive men. As a consequence, there is an
urgent need to characterize and evaluate the outcome of
HAART in HIV-positive women and to identify special
requirements of this particular patient population.
Methods
Cross-sectional multicentre (n = 31 centres) evaluation to
observe characteristics of 1,557 HIV-positive women
receiving medical care in Germany between June 2007
and March 2008. Data acquisition was performed using
standardized questionnaires.
Summary of results
Of 1,557 HIV-positive women studied, 1,191 (77%)
received HAART. Mean age was 40 years and average time
of known HIV-infection was 9 years. Risk of HIV transmis-
sion was: 40% heterosexual intercourse in Germany, 36%
heterosexual intercourse in a high prevalence country;
17% IDU; 7% other reasons for transmission. 46% of the
women had a migration background. Mean time on
antiretroviral treatment was 7 years. 53% of the female
participants had been treated with >2 HAART-regimens.
47% of the study subjects received a PI-based regimen,
33% a NNRTI-based regimen; 20% were on other combi-
nations. The most commonly used PI and NNRTI were
lopinavir/r and nevirapine, respectively. Only 48% of all
women under HAART achieved a viral load <40 copies/
ml. There was a significant difference between the PI-
treated group with 44% patients <40 copies/ml and the
NNRTI-treated group with 56% <40 copies/ml (p =
0.003).
Conclusion
We found that HIV-positive women depicted an inferior
virological response to HAART compared to those previ-
ously published in German cohort analyses dominated by
men (response rates >75%). Possible differences in adher-
ence or drug resistance may have impacted these results
and are currently being evaluated in ongoing sub-analy-
ses. Of note, the lack of a study arm with male patients is
a limitation of this investigation. However, this is partly
off-set by the fact that there are good comparative data in
the male population found in other cohorts. We conclude
that our results are in discordance to the popular assump-
tion that there are no gender specific differences in viro-
logical treatment outcome of HAART.
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